Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.13 USD | +3.30% | -1.88% | +13.00% |
Sales 2024 * | - | Sales 2025 * | 44.27M 3.52B | Capitalization | 109M 8.65B |
---|---|---|---|---|---|
Net income 2024 * | -49M -3.9B | Net income 2025 * | -22M -1.75B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.45 x |
P/E ratio 2024 * |
-1.86
x | P/E ratio 2025 * |
-5.25
x | Employees | 20 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.18% |
Latest transcript on Cellectar Biosciences, Inc.
1 day | +3.30% | ||
1 week | -1.88% | ||
Current month | -21.36% | ||
1 month | -20.15% | ||
3 months | -25.65% | ||
6 months | +30.42% | ||
Current year | +13.00% |
Managers | Title | Age | Since |
---|---|---|---|
James V. Caruso
CEO | Chief Executive Officer | 65 | 14/06/15 |
Chad J. Kolean
DFI | Director of Finance/CFO | 59 | 27/05/14 |
Andrei Shustov
CTO | Chief Tech/Sci/R&D Officer | - | 14/02/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 74 | 06/04/17 |
Douglas Swirsky
CHM | Chairman | 54 | 06/04/17 |
John Neis
BRD | Director/Board Member | 68 | 31/01/08 |
Date | Price | Change | Volume |
---|---|---|---|
29/04/24 | 3.13 | +3.30% | 656 782 |
26/04/24 | 3.03 | +0.33% | 686,677 |
25/04/24 | 3.02 | -1.31% | 690,802 |
24/04/24 | 3.06 | -1.61% | 1,043,212 |
23/04/24 | 3.11 | -2.51% | 899,197 |
Delayed Quote Nasdaq, April 29, 2024 at 08:52 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.00% | 109M | |
+26.24% | 661B | |
+26.74% | 566B | |
-6.37% | 352B | |
+19.16% | 332B | |
+3.97% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.10% | 145B |
- Stock Market
- Equities
- CLRB Stock